"An effective management team is a great predictor of success. I am delighted to be working with such exceptionally talented people. Both Daron and Jenny have years of relevant cardiovascular therapy development experience. As a management team, we are focused on creating value through the development of our lead compound CD-NP for the treatment of heart failure and our pre-clinical, anti-atherothrombotic agent, 2NTX-99," said Peter Strumph, CEO of Nile Therapeutics.
About Nile Therapeutics.
Nile Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is developing innovative products for the treatment of cardiovascular disease. Nile is initially focusing its efforts on developing its lead compound, CD-NP, a novel chimeric peptide in Phase I studies for the treatment of heart failure and 2NTX-99, a small molecule, pre-clinical, anti-atherothrombotic agent with nitric oxide (NO) donating properties.
CD-NP, a novel chimeric natriuretic peptide currently in Phase I
clinical studies for the treatment of heart failure, is a selective NPRB
agonist which, in vivo, has been shown to have potent renal enhancement and
cardiac unloading properties but with minimal hypotensive effects compared
with competitive products. CD-NP is a rationally-designed synthetic peptide
designed to incorporate favorable properties of naturally occurring
natriuretic peptides. Data from Nile's recently completed Phase Ia study in
healthy volunteers confirmed several pre-clinical findings, including that
CD-NP activated its target receptor in humans, preserved renal function and
caused increases in natriuresis and diuresis at doses associated with a
minimal effect on mean arterial pressure. Nile believes that CD-NP could
provide a valuable new treatment option for heart fai
|SOURCE Nile Therapeutics, Inc.|
Copyright©2007 PR Newswire.
All rights reserved